Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nicotinamide riboside - ChromaDex

Next Previous
X
Search
Drug Profile

Nicotinamide riboside - ChromaDex

Alternative Names: NIAGEN; nicotinamide riboside chloride; Nicotinamide-beta-riboside; Nicotinamide-ribonucleoside; Nicotinamide-ribose; NRC; SRT-647

Latest Information Update: 23 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University; Dartmouth College; Washington University
  • Developer ChromaDex; Ecole Polytechnique Federale de Lausanne.; Emory University; National Institutes of Health (USA); University of Cambridge; University of Iowa; Washington University
  • Class Amides; Analgesics; Antivirals; Nicotinic acids; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ataxia telangiectasia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ataxia telangiectasia
  • Discontinued Alzheimer's disease; Cockayne syndrome; COVID 2019 infections; Heart failure; Mitochondrial myopathies; Pain; Retinal disorders

Most Recent Events

  • 19 Aug 2024 ChromaDex has patent protection for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide)
  • 14 Aug 2024 9423014: No updates
  • 07 Jun 2024 Preclinical trials in Ataxia telangiectasia in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top